Literature DB >> 8151562

Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies.

M Blank1, A Tincani, Y Shoenfeld.   

Abstract

OBJECTIVE: It is accepted that antiphospholipid syndrome (APS) is due to the presence of anticardiolipin antibodies (aCL). Since phosphatidylserine is a negatively charged phospholipid, we tried to demonstrate the pathogenic role of antiphosphatidylserine in APS.
METHODS: We used affinity purified IgG antiphosphatidylserine antibodies from sera of 2 patients with APS characterized by recurrent thromboembolic phenomena, recurrent fetal loss and prolonged activated partial thromboplastin time (aPTT). In one patient the antiphosphatidylserine Abs were the main antiphospholipid antibody (aPL) while the 2nd patient also had pathogenic aCL. The purified antibodies were passively infused into the tail vein of mice. The mice were mated and we followed them for manifestations of APS.
RESULTS: Passive infusion of IgG but not IgM antiphosphatidylserine antibodies to pregnant ICR mice resulted in increased fetal resorption rate (40%), lower mean weights of the placentae and fetuses and prolonged aPTT (82 s). Antiphosphatidylserine antibodies were detected in the placentae.
CONCLUSIONS: Our results point to the pathogenic role of antiphosphatidylserine antibodies and emphasize the importance of looking for the presence of antiphosphatidylserine Abs in sera of patients with clinical manifestations compatible with APS even in the absence of aCL Abs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151562

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome.

Authors:  Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 2.  Multiple autoantibodies associated with autoimmune reproductive failure.

Authors:  Yaniv Sherer; Shelly Tartakover-Matalon; Miri Blank; Eiji Matsuura; Yehuda Shoenfeldlt
Journal:  J Assist Reprod Genet       Date:  2003-02       Impact factor: 3.412

3.  Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice.

Authors:  I Krause; M Blank; Y Shoenfeld
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

4.  Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression.

Authors:  I Krause; M Blank; Y Levi; T Koike; V Barak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

5.  Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway.

Authors:  Melissa J Mulla; Jan J Brosens; Larry W Chamley; Ian Giles; Charis Pericleous; Anisur Rahman; Shawna K Joyce; Britta Panda; Michael J Paidas; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2009-08       Impact factor: 3.886

6.  Natural autoantibodies in sera of patients with Gaucher's disease.

Authors:  Y Shoenfeld; A Beresovski; D Zharhary; Y Tomer; M Swissa; E Sela; A Zimran; S Zevin; B Gilburd; M Blank
Journal:  J Clin Immunol       Date:  1995-11       Impact factor: 8.317

7.  Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti-beta2-glycoprotein-I autoantibodies.

Authors:  Anjana Singh; Miri Blank; Yehuda Shoenfeld; Harald Illges
Journal:  Rheumatol Int       Date:  2008-01-03       Impact factor: 2.631

8.  Investigation of antiphosphatidyl-serine antibody and antiphosphatidyl-inositol antibody in ischemic stroke patients.

Authors:  Hirohisa Okuma; Yasuhisa Kitagawa; Shigeharu Takagi
Journal:  Clin Dev Immunol       Date:  2010-12-20

9.  Antibody targeting of phosphatidylserine for detection and immunotherapy of cancer.

Authors:  Daniela Noa Zohar; Yehuda Shoenfeld
Journal:  Immunotargets Ther       Date:  2018-06-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.